Aerie is focused on the discovery, development and commercialization of first-in-class therapies for patients with glaucoma and other diseases of the eye. GrayBug develops microparticle controlled release drug
As part of the deal, a Phase I/II trial will be conducted to evaluate the safety and efficacy of MedImmune’s durvalumab (MEDI4736) in combination with Mirati’s mocetinostat in
The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA)for this product to treat GERD. According to IMS
The randomized, crossover study Phase IIb trial is designed to evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in
The company noted that in a Phase I trial, low-dose veltuzumab, as a single agent, produced an objective response rate of 55% in 38 response-assessable patients with relapsed
The EC’s decision includes Pfizer’s commitment to divest certain sterile injectable drugs and its infliximab biosimilar drug, which is currently under development. Pfizer chairman and chief executive officer
ALX-0061 targets the interleukin 6 pathway via its IL-6 receptor (IL-6R) and is being developed to treat rheumatoid arthritis (RA) and SLE. The trial is designed to identify
A4 is a new clinical trial evaluating solanezumab in the preclinical stage of Alzheimer’s disease in older individuals who have evidence of amyloid in their brains on a
Par’s ethacrynate sodium is the generic version of Valeant Pharmaceuticals North America division Aton Pharma’s Sodium Edecrin, which is indicated for the treatment of edema. According to the
The proposal made by Shire was to combine the companies in an all-stock transaction pursuant to which Baxalta shareholders would receive, for each Baxalta share, 0.1687 Shire ADRs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.